E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium

Genes Chromosomes and Cancer

Volumn 51, Issue 11, 2012, Pages 1054-1062

  Smith, Na Lu ^a   Welcsh, Piri ^a   Press, Joshua Z ^b   Agnew, Kathy J ^a   Garcia, Rochelle ^a   Swisher, Elizabeth M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; ONCOGENE E2F3A; ONCOGENE E2F3B; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE TUBE; UTERINE TUBE CARCINOMA;

ADULT; AGED; BRCA1 PROTEIN; E2F3 TRANSCRIPTION FACTOR; EPITHELIUM; FALLOPIAN TUBES; FEMALE; GENE AMPLIFICATION; HAPLOINSUFFICIENCY; HISTOCYTOCHEMISTRY; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865979215     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21990     Document Type: Article

References (29)

1. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. 2000. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 20: 3633-3639.
2. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. 2001. Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25: 1283-1289.
3. Crum CP. 2009. Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol Oncol 3: 165-170.
4. Crum CP, Xian W. 2010. Bringing the p53 signature into focus. Cancer 116: 5119-5121.
5. Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, Bronson RT, Lees JA. 2008. E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene 27: 6561-6570.
6. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP. 2008. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109: 168-173.
7. He Y, Armanious MK, Thomas MJ, Cress WD. 2000. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 19: 3422-3433.
8. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G. 2001. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539-548.
9. Iaquinta PJ, Lees JA. 2007. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 19: 649-657.
10. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. 2002. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94: 990-1000.
11. Karst AM, Drapkin R. 2010. Ovarian cancer pathogenesis: A model in evolution. J Oncol 2010: 932371.
12. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. 2007. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31: 161-169.
13. Kovesdi I, Reichel R, Nevins JR. 1986a. E1A transcription induction: Enhanced binding of a factor to upstream promoter sequences. Science 231: 719-722.
14. Kovesdi I, Reichel R, Nevins JR. 1986b. Identification of a cellular transcription factor involved in E1A trans-activation. Cell 45: 219-228.
15. Kurman RJ, Shih IeM. 2010. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 34: 433-443.
16. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP. 2007. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211: 26-35.
17. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. 2002. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87: 52-56.
18. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR. 2000. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 20: 3626-3632.
19. Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC. 2011. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 30: 417-424.
20. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr. 2004. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300.
21. Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM. 2010. The molecular pathogenesis of hereditary ovarian carcinoma: Alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116: 5261-5271.
22. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J. 2005. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23: 127-132.
23. Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM. 2010. Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia 12: 993-1002.
24. Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R. 2010. Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin? Am J Surg Pathol 34: 1407-1416.
25. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Muller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG. 2010. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res 70: 4613-4623.
26. Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Muller-Holzner E, Marth C, Altevogt P, Zeimet AG. 2011. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene 30: 4038-4049.
27. Sears RC, Nevins JR. 2002. Signaling networks that link cell proliferation and cell fate. J Biol Chem 277: 11617-11620.
28. von Eyss B, Maaskola J, Memczak S, Mollmann K, Schuetz A, Loddenkemper C, Tanh MD, Otto A, Muegge K, Heinemann U, Rajewsky N, Ziebold U. 2011. The SNF2-like helicase HELLS mediates E2F3-dependent transcription and cellular transformation. EMBO J 31: 972-985.
29. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayke A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM. 2011. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108: 18032-18037.